concept

NEUROPROTECTION

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about NEUROPROTECTION: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

361Connections

23Hypotheses

30Analyses

31Outgoing

50Incoming

3Experiments

20Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	NEUROPROTECTION
Key Genes/Proteins	Aucubin
Related Diseases	NEURODEGENERATION

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

Sulforaphane and Nrf2 Activation for Neuroprotection

therapeutic · 4477 words

→

Pathway Diagram

graph TD
    NEUROPROTECTION["NEUROPROTECTION"]
    style NEUROPROTECTION fill:#1a237e,stroke:#4fc3f7,stroke-width:3px
    NEUROPROTECTION -.->|"protects against"| Glaucoma["Glaucoma"]
    NEUROPROTECTION -.->|"protects against"| Neurodegeneration["Neurodegeneration"]
    NEUROPROTECTION -.->|"protects against"| Axonal_Damage(Axonal Damage)
    NEUROPROTECTION -.->|"protects against"| major_depressive_disorder["major depressive disorder"]
    NEUROPROTECTION -.->|"inhibits"| NEURODEGENERATION(NEURODEGENERATION)
    NEUROPROTECTION -.->|"protects against"| PPAR["PPAR"]
    NEUROPROTECTION -.->|"protects against"| VDR["VDR"]
    NEUROPROTECTION -.->|"protects against"| PARKIN["PARKIN"]
    NEUROPROTECTION -->|"activates"| NRF2["NRF2"]
    Connexin43_Hemichannel_Blockad["Connexin43 Hemichannel Blockade"] -->|"mediates"| NEUROPROTECTION
    MT1([MT1]) -->|"involved_in"| NEUROPROTECTION
    MT2([MT2]) -->|"involved_in"| NEUROPROTECTION
    Tudca["Tudca"] -->|"mediates"| NEUROPROTECTION
    AKT([AKT]) -->|"involved_in"| NEUROPROTECTION
    METALLOTHIONEIN([METALLOTHIONEIN]) -->|"mediates"| NEUROPROTECTION
    METALLOTHIONEIN_I_II([METALLOTHIONEIN-I+II]) -->|"involved_in"| NEUROPROTECTION
    PPARG["PPARG"] -->|"mediates"| NEUROPROTECTION
    BDNF_TrkB_signaling["BDNF/TrkB signaling"] -->|"promotes"| NEUROPROTECTION
    microglial_APOE4_deletion["microglial APOE4 deletion"] -->|"promotes"| NEUROPROTECTION

Outgoing (31)

Target	Relation	Type	Str
Axonal Damage	protects_against	phenotype	0.85
Neurodegeneration	protects_against	process	0.85
Glaucoma	protects_against	disease	0.85
major depressive disorder	protects_against	disease	0.80
Alzheimer's Disease	protects_against	disease	0.75
NEURODEGENERATION	inhibits	phenotype	0.64
PI3K	activates	entity	0.60
SLC7A11	activates	entity	0.60
STROKE	protects_against	entity	0.60
NLGN3	activates	entity	0.60
NRF2	inhibits	entity	0.60
SLC7A11	inhibits	entity	0.60
STROKE	inhibits	entity	0.60
STROKE	biomarker_for	entity	0.60
NRF2	activates	entity	0.60
PPAR	protects_against	entity	0.60
PPAR	activates	entity	0.60
PARKIN	protects_against	entity	0.60
VDR	protects_against	entity	0.60
ISCHEMIC STROKE	protects_against	concept	0.50
ISCHEMIC STROKE	inhibits	concept	0.50
MAPK SIGNALING	activates	concept	0.50
REMYELINATION	inhibits	concept	0.50
IGF-1	activates	concept	0.50
PI3K/AKT SIGNALING	activates	concept	0.50
GLIOSIS	activates	concept	0.50
CENTRAL NERVOUS SYSTEM	activates	concept	0.50
CENTRAL NERVOUS SYSTEM	decreases_risk	concept	0.50
ISCHEMIC STROKE	activates	concept	0.50
MICROGLIAL ACTIVATION	activates	concept	0.50
QUERCETIN	interacts_with	concept	0.50

Incoming (330)

Source	Relation	Type	Str
Tudca	mediates	compound	0.95
METALLOTHIONEIN-I+II	involved_in	protein	0.95
mitochondrial_transfer	mediates	mechanism	0.95
Connexin43 Hemichannel Blockade	mediates	mechanism	0.95
MT2	involved_in	protein	0.95
METALLOTHIONEIN	mediates	protein	0.95
AKT	involved_in	protein	0.95
MT1	involved_in	protein	0.95
BDNF/TrkB signaling	promotes	pathway	0.92
microglial APOE4 deletion	promotes	process	0.91
Lactate	protective_against	metabolite	0.90
Berberine-Inspired Ionizable Lipid	promotes	compound	0.90
mitochondrial_transfer	contributes_to	mechanism	0.90
Microglia	mediates	cell_type	0.90
Gd3 Synthase	mediates	enzyme	0.90
NO	mediates	compound	0.90
NAD+/SIRT1 axis restoration	causes	pathway	0.90
Methylene Blue	promotes	drug	0.90
Cerebral Insulin Signaling	mediates	pathway	0.90
Astrocytes	mediates	cell_type	0.90
GJA1	modulates	protein	0.90
Connexin43 Hemichannel Blockade	activates	mechanism	0.90
TGR5	mediates	receptor	0.90
INTESTINAL NHR-86	mediates	protein	0.90
Exercise	causes	phenotype	0.90
butyrate	decreases_risk	drug	0.90
mitophagy	promotes	process	0.88
Atremorine	mediates	compound	0.88
Hk2-Pink1 Pathway	mediates	pathway	0.88
APOE4	inhibits	gene	0.88
BDNF	mediates	gene	0.88
mitophagy enhancement	promotes	process	0.87
PRKN	protects_against	protein	0.85
MicroRNAs	mediates	biomarker	0.85
SHH signaling pathway	mediates	pathway	0.85
Polyphenols	mediates	compound	0.85
Exosome-Based Treatments	promotes	drug	0.85
STING Inhibition	protects_against	mechanism	0.85
lncRNAs	mediates	biomarker	0.85
HDAC3 Inhibition	mediates	mechanism	0.85
HK2-PINK1 pathway	promotes	pathway	0.85
Long Non-Coding RNAs	mediates	biomarker	0.85
Hk2-Pink1	promotes	pathway	0.85
Macrophage/Microglia Autophagy	protects_against	process	0.85
APOE Ε4	inhibits	protein	0.85
Pi3K/Akt Pathway	mediates	pathway	0.85
A2 Astrocytes	mediates	cell_type	0.85
NFE2L2	mediates	gene	0.85
MAPK Signaling Pathway	mediates	pathway	0.85
Tryptophan Metabolites	mediates	compound	0.85

Targeting Hypotheses (23)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
TYROBP (DAP12) Conditional Antagonism for Early-Stage Neurop	0.844	neurodegeneration	Gene Co-expression Network Analysis of A
NLRP3 Inflammasome Inhibition for Neuroprotection in Parkins	0.720	neurodegeneration	Test
NRF2 Activation Provides Neuroprotection Across ALS, AD, and	0.710	neurodegeneration	Test Preregistration Analysis
Ferroptosis Inhibition for α-Synuclein Neuroprotection	0.705	neurodegeneration	Gene expression changes in aging mouse b
GLUT1-Mediated Glucose Flux Coefficient as Neuroprotection I	0.685	translational-neuroscience	Which metabolic biomarkers can distingui

CX3CL1-CX3CR1 Mimetic Therapy for Neuroprotection	0.635	neurodegeneration	Microglial subtypes in neurodegeneration
DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against T	0.604	neurodegeneration	Should microtubule-stabilizing drugs be
Female Microglia Exhibit Reduced P2Y12 Expression Conferring	0.580	neuroinflammation	How do regional, age, and sex-dependent
Purine Salvage Pathway Flux as Neuroprotection Efficacy Mark	0.565	translational-neuroscience	Which metabolic biomarkers can distingui
CSF1R Partial Agonism Combined with TREM2 Activation for ALS	0.535	neurodegeneration	Microglial subtypes in neurodegeneration
Mitochondrial Biogenesis Rate as a Dynamic Biomarker of Neur	0.503	translational-neuroscience	Which metabolic biomarkers can distingui
Mitochondrial-Targeted PINK1/Parkin Pathway Activation for N	0.500	neurodegeneration	Test Hypothesis Fixtures
Time-Restricted High-Dose Melatonin for Acute Neuroprotectio	0.445	-	What is the optimal dosage and timing of
Microbiome-Derived Tryptophan Metabolite Neuroprotection	0.427	neurodegeneration	What are the mechanisms by which gut mic
Serotonergic 5-HT1A/1B Agonism for Neuroprotection	0.420	neurodegeneration	Test
LRP1-ARF1 Lactylation Inhibitors for Metabolic Neuroprotecti	0.000	-	Mitochondrial transfer between astrocyte
Retinal Microvascular Neuroprotection	0.000	-	Digital biomarkers and AI-driven early d
Circadian-Metabolic Coupling for Neuroprotection	0.000	-	Sleep disruption as cause and consequenc
RNA-Guided Condensate Reprogramming for Neuroprotection	0.000	-	What determines the specificity of DDR p
Ginsenoside Rb1 Analogs for Complex I-Mediated Neuroprotecti	0.000	-	Mitochondrial transfer between astrocyte
Astrocyte Priming Therapy for Preconditioning Neuroprotectio	0.000	-	Mitochondrial transfer between astrocyte
NRF2 Pathway Activation for Neuroprotection	0.000	-	4R-tau strain-specific spreading pattern
Multi-Target Synbiotic Platform for Simultaneous Neuroprotec	0.000	-	Gut-Brain Axis Therapeutics for Alzheime

Mentioning Analyses (30)

Scientific analyses that reference this entity

What is the minimum effective dose of trazodone required for disease-modifying e

neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.605

What is the optimal dosage and timing of melatonin administration for AD prevent

neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.735

Gut-Brain Axis in Parkinson's Disease: Molecular Mechanisms, Neuroinflammation,

neurodegeneration | 2026-04-26 | 4 hypotheses Top: 0.630

Comparative epigenetic signatures: DNA methylation age acceleration and histone

neurodegeneration | 2026-04-18 | 0 hypotheses

Analyze the spectrum of microglial activation states (DAM, homeostatic, inflamma

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.627

Experiments (3)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
S-equol-induced ferroptosis mechanism in TNBC cells	exploratory	Triple negative breast cancer	0.900	0.00	TNBC cell lines	proposed	N/A
Gandouling protection against brain injury in Wilson's disease via SIR	validation	Hepatolenticular degeneration	0.900	0.00	TX mice (Wilson's disease mode	proposed	N/A
Conditional TYROBP Knockdown in Early-Stage 5xFAD Mice Using CRISPRi-A	in_vivo	Alzheimer's disease	0.746	0.55	5xFAD x Cx3cr1-Cre mice inject	abandoned	$95,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
Genome-wide consensus transcriptional signatures identify synaptic pruning linki [PMID:41139712]	Li H, Xie Z, Tian Y, Zhou R, Yang Y et a	Mol Psychiatry	2026
The Alzheimer's disease risk genes MS4A4A and MS4A6A cooperate to negatively reg [PMID:41435829]	Rosner D, Sun J, Cacace R, Yee A, Wagh C	Neuron	2026
GPX4 promotes optic nerve regeneration and retinal ganglion cell neuroprotection [PMID:41485051]	Yang M, Bian F, Feng X, Li L, Huang H et	Mol Ther	2026
Extracellular GPX4 impairs antitumor immunity via dendritic ZP3 receptors. [PMID:41494530]	Liu J, Cai X, Lin J, Zhang Z, Zhou Q et	Cell	2026
Aging at the Crossroads of Cuproptosis and Ferroptosis: From Molecular Pathways [PMID:41516398]	Gromadzka G, Tarnacka B, Cieślik M	Int J Mol Sci	2026
Integrative Transcriptomic and Bioinformatics Approaches Combined With Transform [PMID:41524613]	Yan D, Li W, Xing E, Wang P, Zhang Z	FASEB J	2026
Ferroptosis in neurological diseases: moving towards therapeutic intervention. [PMID:41554903]	Tuo QZ, Bush AI, Lei P	Mol Psychiatry	2026
Fin(e)-tuning ferroptosis. [PMID:41576911]	Szylo KJ, Dixon SJ	Mol Cell	2026
GPX4-dependent ferroptosis governs ILC2 homeostasis and colitis progression. [PMID:41663525]	Liu G, Wang Y, Huang H, Wang J, Yang J e	Cell Mol Immunol	2026
A GPX1-OSBPL8 axis mediates noncanonical in vivo ferroptosis and cancer growth s [PMID:41720096]	Xia Z, Yang X, Samovich SN, Tyurina YY,	Cell	2026
The crossroads of inflammation and oxidative stress: A review of the interplay b [PMID:41722697]	Park WH	Pharmacol Res	2026
Ferroptosis in Cerebral Ischemia/Reperfusion Injury: Mechanistic Drivers and The [PMID:41738060]	Song C, Liu Z, Tang J, Huang Y	Neuropsychiatr Dis Treat	2026
Decoding GPX4 regulation in ferroptosis: mechanisms and therapeutic implications [PMID:41826143]	Chen X	Trends Mol Med	2026
Integrative bioinformatics and machine learning identify shared molecular mechan [PMID:41961800]	Deng A, Wang W	PLoS One	2026
Montelukast Modulates MPTP-induced Ferroptosis and Neuroinflammation Linked To t [PMID:41712018]	["Jung Yu Jin", "Choi Hyunsu", "Lee Seon	Neuromolecular medicine	2026
A fin-loop-like structure in GPX4 underlies neuroprotection from ferroptosis. [PMID:41349546]	Lorenz SM, Wahida A, Bostock MJ, Seibt T	Cell	2026
Genome-wide consensus transcriptional signatures identify synaptic pruning linki [PMID:41139712]	Li H, Xie Z, Tian Y, Zhou R, Yang Y, Lin	Molecular psychiatry	2026
The Alzheimer's disease risk genes MS4A4A and MS4A6A cooperate to negatively reg [PMID:41435829]	Rosner D, Sun J, Cacace R, Yee A, Wagh C	Neuron	2026
Hypoxia-inducible factor-1 as targets for neuroprotection : from ferroptosis to [PMID:39466326]	["Changyong Wang", "Shanyu Lv", "Hongyan	Neurological sciences : offici	2025
Gentiopicroside Attenuated Dopaminergic Neurodegeneration via Inhibiting Neuroin [PMID:40256942]	Unknown	Basic & clinical pharmacol	2025

Debates (20)

Multi-agent debates referencing this entity

Extended debate: CYP46A1 Overexpression Gene Therapy

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Debate: Enhancing Microglial Phagocytosis of Extracellular Tau via TREM2 Activat

closed · Rounds: 4 · Score: 0.34 · 2026-04-27

Hypothesis debate: Membrane Cholesterol Gradient Modulators

closed · Rounds: 4 · Score: 0.50 · 2026-04-27

Hypothesis debate: Microbial Inflammasome Priming Prevention

closed · Rounds: 4 · Score: 0.48 · 2026-04-27

Hypothesis debate: Selective Acid Sphingomyelinase Modulation Therapy

closed · Rounds: 4 · Score: 0.40 · 2026-04-27

Hypothesis debate: CYP46A1 Overexpression Gene Therapy

closed · Rounds: 4 · Score: 0.40 · 2026-04-27

What is the minimum effective dose of trazodone required for disease-modifying e

closed · Rounds: 4 · Score: 1.00 · 2026-04-26

What is the optimal dosage and timing of melatonin administration for AD prevent

closed · Rounds: 4 · Score: 1.00 · 2026-04-26

Hypothesis debate: SCFA Deficiency Disrupts Microglial Homeostasis and Promotes

closed · Rounds: 4 · Score: 0.60 · 2026-04-26

Hypothesis debate: Vagus Nerve as Anatomical Highway for Prion-Like α-Syn Propag

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Related Research

Hypotheses and analyses mentioning NEUROPROTECTION in their description or question text

CX3CL1-CX3CR1 Mimetic Therapy for Neuroprotection

Score: 0.635 · neurodegeneration · 2026-04-25

Second priority with excellent tractability (GPCR). F1can designated orphan drug in Japan provides development precedent

DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against Tau-Induced Destabili

Score: 0.604 · neurodegeneration · 2026-04-15

## Mechanistic Overview DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against Tau-Induced Destabilization starts fr

Female Microglia Exhibit Reduced P2Y12 Expression Conferring Neuroprotection Thr

Score: 0.580 · neuroinflammation · 2026-04-22

## Mechanistic Overview Female Microglia Exhibit Reduced P2Y12 Expression Conferring Neuroprotection Through Attenuated

Purine Salvage Pathway Flux as Neuroprotection Efficacy Marker

Score: 0.565 · translational-neuroscience · 2026-04-16

## Mechanistic Overview Purine Salvage Pathway Flux as Neuroprotection Efficacy Marker starts from the claim that modula

CSF1R Partial Agonism Combined with TREM2 Activation for ALS Neuroprotection

Score: 0.535 · neurodegeneration · 2026-04-25

Premature investment. The Expert identifies that no validated partial CSF1R agonist exists—creating partial agonism for

Mitochondrial Biogenesis Rate as a Dynamic Biomarker of Neuroprotection

Score: 0.503 · translational-neuroscience · 2026-04-12

## Mechanistic Overview Mitochondrial Biogenesis Rate as a Dynamic Biomarker of Neuroprotection starts from the claim th

Mitochondrial-Targeted PINK1/Parkin Pathway Activation for Neuroprotection

Score: 0.500 · neurodegeneration · 2026-04-26

PINK1 loss-of-function prevents Parkin recruitment to damaged mitochondria, blocking mitophagy. Urolithin A is proposed

Time-Restricted High-Dose Melatonin for Acute Neuroprotection

Score: 0.445 · unknown disease · 2026-04-26

Nightly 10mg melatonin dosing attenuates Aβ42-induced neurotoxicity through MT1-mediated suppression of PERK/CHOP apopto

Microbiome-Derived Tryptophan Metabolite Neuroprotection

Score: 0.427 · neurodegeneration · 2026-04-02

Beneficial gut bacteria convert dietary tryptophan into neuroprotective metabolites like indole-3-propionic acid, which

Serotonergic 5-HT1A/1B Agonism for Neuroprotection

Score: 0.420 · neurodegeneration · 2026-05-04

Serotonergic dysfunction precedes motor symptoms in PD; 5-HT1A/1B agonism proposed to reduce neuroinflammation. Despite